Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging placebo-controlled study of BI 456906 in adults with biopsy-confirmed NASH and liver fibrosis
MOH_2021-12-14_010096Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Dose-response in histologic improvement at week 48. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2021-12-14_010096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-14_010096.